NCT06190158View on ClinicalTrials.gov

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
Type 2 DiabetesChronic Kidney Diseases
Interventions
DIAGNOSTIC_TEST

Oral sodium suppression test

Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)

DIAGNOSTIC_TEST

Saline suppression test

Saline suppression test (2 liters of saline)

DIAGNOSTIC_TEST

Captopril suppression test

Captopril suppression test (50mg of captopril)

DIAGNOSTIC_TEST

Dexamethasone suppression test

1mg of dexamethasone

DIAGNOSTIC_TEST

Cosyntropin stimulation test

250mcg of cosyntropin

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER